Miguel Regueiro

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
    Mark S Silverberg
    Mount Sinai Hospital Inflammatory Bowel Disease Group, University of Toronto, 600 University Avenue, Toronto, ON M5G1X5, Canada
    Nat Genet 41:216-20. 2009
  2. doi request reprint The evolving management of postoperative Crohn's disease
    Jana G Hashash
    Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street PUH, M2, C Wing, Pittsburgh, PA 15213, USA
    Expert Rev Gastroenterol Hepatol 6:637-48. 2012
  3. ncbi request reprint Maximizing the effect of biologics in inflammatory bowel disease
    R Souto Rodriguez
    Universitario de Santiago de Compostela, Santiago de Compostela, Spain
    Minerva Gastroenterol Dietol 58:101-22. 2012
  4. doi request reprint Infliximab prevents Crohn's disease recurrence after ileal resection
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Gastroenterology 136:441-50.e1; quiz 716. 2009
  5. doi request reprint Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease
    Miguel Regueiro
    Division of Gastroenterology, Hepatology and Nutrition, Inflammatory Bowel Disease Center, University of Pittsburgh School of Medicine, 200 Lothrop Street, PUH C Wing Mezzanine Level, Pittsburgh, PA 15213, USA
    Dig Dis Sci 56:3610-5. 2011
  6. ncbi request reprint Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease
    Benjamin Siemanowski
    Miguel Regueiro, MD Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street, PUH C Wing Mezzanine Level, Pittsburgh, PA 15213, USA
    Curr Treat Options Gastroenterol 10:178-84. 2007
  7. ncbi request reprint Infliximab dose intensification in Crohn's disease
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, Department of Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 13:1093-9. 2007
  8. doi request reprint Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 17:118-26. 2011
  9. doi request reprint Management and prevention of postoperative Crohn's disease
    Miguel Regueiro
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 15:1583-90. 2009
  10. ncbi request reprint Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 12:979-94. 2006

Collaborators

Detail Information

Publications34

  1. pmc Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
    Mark S Silverberg
    Mount Sinai Hospital Inflammatory Bowel Disease Group, University of Toronto, 600 University Avenue, Toronto, ON M5G1X5, Canada
    Nat Genet 41:216-20. 2009
    ..0 x 10(-16), combined OR = 0.66) and at the IL23R locus on chromosome 1p31 (rs11209026, combined P = 1.3 x 10(-8), combined OR = 0.56; rs10889677, combined P = 1.3 x 10(-8), combined OR = 1.29)...
  2. doi request reprint The evolving management of postoperative Crohn's disease
    Jana G Hashash
    Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street PUH, M2, C Wing, Pittsburgh, PA 15213, USA
    Expert Rev Gastroenterol Hepatol 6:637-48. 2012
    ....
  3. ncbi request reprint Maximizing the effect of biologics in inflammatory bowel disease
    R Souto Rodriguez
    Universitario de Santiago de Compostela, Santiago de Compostela, Spain
    Minerva Gastroenterol Dietol 58:101-22. 2012
    ..Finally, the role of antibody to infliximab (ATI) and infliximab serum trough levels are discussed in the context of optimizing biologic therapy for inflammatory bowel disease...
  4. doi request reprint Infliximab prevents Crohn's disease recurrence after ileal resection
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Gastroenterology 136:441-50.e1; quiz 716. 2009
    ..Crohn's disease commonly recurs after intestinal resection. We evaluated whether the administration of infliximab after resective intestinal surgery for Crohn's disease reduces postoperative recurrence...
  5. doi request reprint Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease
    Miguel Regueiro
    Division of Gastroenterology, Hepatology and Nutrition, Inflammatory Bowel Disease Center, University of Pittsburgh School of Medicine, 200 Lothrop Street, PUH C Wing Mezzanine Level, Pittsburgh, PA 15213, USA
    Dig Dis Sci 56:3610-5. 2011
    ..It is not known whether administration of infliximab shortly after resective surgery for Crohn's disease increases postoperative complications...
  6. ncbi request reprint Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease
    Benjamin Siemanowski
    Miguel Regueiro, MD Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street, PUH C Wing Mezzanine Level, Pittsburgh, PA 15213, USA
    Curr Treat Options Gastroenterol 10:178-84. 2007
    ..Whether long-term infliximab therapy is necessary to maintain remission of EIMs, as in the case of IBD, has not been established...
  7. ncbi request reprint Infliximab dose intensification in Crohn's disease
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, Department of Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 13:1093-9. 2007
    ..The aims of this study were to determine the proportion of CD patients who require dose intensification and factors associated with dose intensification...
  8. doi request reprint Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 17:118-26. 2011
    ..We evaluated the extent of agreement between clinical recurrence/remission as defined by the CDAI and endoscopic recurrence 1 year after intestinal resection for Crohn's disease (CD)...
  9. doi request reprint Management and prevention of postoperative Crohn's disease
    Miguel Regueiro
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 15:1583-90. 2009
    ..This review discusses current evidence for various pharmacologic approaches in the prevention of postoperative recurrence and provides guidance for clarifying patient risk...
  10. ncbi request reprint Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 12:979-94. 2006
    ..The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement...
  11. ncbi request reprint Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 12:972-8. 2006
    ..Those who have ongoing signs and symptoms of ulcerative proctitis and left-sided ulcerative colitis despite maximal medical therapy require a proctocolectomy...
  12. ncbi request reprint Infliximab for hospitalized patients with severe ulcerative colitis
    Miguel Regueiro
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Gastroenterol 40:476-81. 2006
    ..In this open-label analysis, infliximab was not effective for the majority of UC patients refractory to intravenous corticosteroids. Whether earlier use of infliximab would prevent the need for hospitalization and colectomy is uncertain...
  13. ncbi request reprint Cigarette smoking and age at diagnosis of inflammatory bowel disease
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Inflamm Bowel Dis 11:42-7. 2005
    ....
  14. doi request reprint Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 17:1008-14. 2011
    ..The aim was to assess the level of agreement between physician's clinical impression of UC disease activity and endoscopic and histologic findings of inflammation...
  15. doi request reprint Prevention and treatment of postoperative Crohn's disease recurrence: an update for a new decade
    Marc Schwartz
    University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Curr Gastroenterol Rep 13:95-100. 2011
    ..If active inflammation is found, then treatment should be intensified. By treating CD aggressively after a first surgery, future surgeries can be delayed or averted...
  16. doi request reprint Preventive therapy in postoperative Crohn's disease
    Jason M Swoger
    University of Pittsburgh Medical Center, Division of Gastroenterology, Hepatology and Nutrition, Pittsburgh, Pennsylvania 15213, USA
    Curr Opin Gastroenterol 26:337-43. 2010
    ..Recent developments in the prevention and management of postoperative recurrence have provided additional information...
  17. ncbi request reprint Intravenous cyclosporine in severe ulcerative colitis: how low can you go?
    Miguel Regueiro
    Inflammatory Bowel Disease Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Inflamm Bowel Dis 10:170. 2004
  18. doi request reprint Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium
    Mark Lazarev
    Division of Gastroenterology, Meyerhoff Inflammatory Bowel Diseases Center, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Am J Gastroenterol 108:106-12. 2013
    ..Our aim was to determine the influence of proximal disease on outcomes of behavior and need for surgery and to determine if there was significant clinical heterogeneity between EGD and jejunal disease...
  19. doi request reprint Postoperative Crohn's disease: prevention and treatment
    Sandra El-Hachem
    Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Expert Rev Gastroenterol Hepatol 3:249-56. 2009
    ..Of these, few have demonstrated consistent efficacy. A recently published randomized, controlled trial indicated that infliximab is effective in the maintenance of postoperative remission...
  20. doi request reprint Clinical course of Crohn's disease following treatment of lymphoma
    Marwa El Mourabet
    Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Inflamm Bowel Dis 17:1265-9. 2011
    ..There are limited data regarding the natural history of CD following treatment of lymphoma. We present a series of CD patients who were treated for lymphoma and describe the natural history of their CD following lymphoma treatment...
  21. doi request reprint Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center
    Mark Lazarev
    Department of Medicine, Division of Gastroenterology, The Harvey M and Lyn P Meyerhoff Inflammatory Bowel Disease Center, Johns Hopkins University Medical Institutions, Baltimore, Maryland, USA
    Inflamm Bowel Dis 16:830-5. 2010
    ..A secondary aim was to establish whether the indication for surgery has changed...
  22. ncbi request reprint A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
    Richard H Duerr
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Pittsburgh, University of Pittsburgh Medical Center Presbyterian, Mezzanine Level, C Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Science 314:1461-3. 2006
    ..These results and previous studies on the proinflammatory role of IL-23 prioritize this signaling pathway as a therapeutic target in inflammatory bowel disease...
  23. pmc Recurrent blood eosinophilia in ulcerative colitis is associated with severe disease and primary sclerosing cholangitis
    Arthur Barrie
    Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Dig Dis Sci 58:222-8. 2013
    ..A subset of IBD patients develops blood eosinophilia, and the clinical profile of these patients is undefined. We sought to characterize IBD patients with and without eosinophilia...
  24. doi request reprint Evaluation for postoperative recurrence of Crohn disease
    Jason M Swoger
    Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street, C Wing, Mezzanine, Pittsburgh, PA 15213, USA
    Gastroenterol Clin North Am 41:303-14. 2012
    ....
  25. doi request reprint Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
    Kofi Clarke
    Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pennsylvania 15213, USA
    Inflamm Bowel Dis 18:174-9. 2012
    ..Where evidence-based data are lacking, the authors provide their opinion...
  26. doi request reprint Postoperative management of crohn disease
    Su Min Cho
    Department of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Gastroenterol Clin North Am 38:753-62. 2009
    ..Postoperative colonoscopy within 1 year of resective surgery is important for identification of disease recurrence and modification of medications...
  27. ncbi request reprint Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease
    Miguel Regueiro
    University of Pittsburg School of Medicine, Inflammatory Bowl Disease Center, Presbyterian Hospital, PA 15261, USA
    J Clin Gastroenterol 35:240-4. 2002
    ..Thiopurine methyltransferase (TPMT) is an enzyme responsible for the metabolism of AZA, and its activity is inversely related to the risk of developing acute leukopenia...
  28. ncbi request reprint The role of endoscopy in the evaluation of fistulizing Crohn's disease
    Miguel Regueiro
    Inflammatory Bowel Disease Center, University of Pittsburgh, School of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Scaife Hall, Room 566, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    Gastrointest Endosc Clin N Am 12:621-33. 2002
    ..Endoscopic therapy for Crohn's fistula is less certain, but may allow for dilation of associated strictures, and may someday serve as a better delivery system for targeted anticytokine and immunologically based therapy...
  29. ncbi request reprint Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease
    Arthur Barrie
    Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Inflamm Bowel Dis 13:1424-9. 2007
    ..This article reviews the therapeutic experiences of the 2 most widely used anti-TNF neutralizing antibodies, infliximab and adalimumab, for immune-mediated EIM of IBD...
  30. ncbi request reprint Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement
    Miguel Regueiro
    University of Pittsburgh School of Medicine, Presbyterian Hospital, Pittsburgh, Pennsylvania 15261, USA
    Inflamm Bowel Dis 9:98-103. 2003
    ..6 months, p = 0.0001) compared with patients receiving infliximab alone. In conclusion, patients with fistulizing CD treated with infliximab are more likely to maintain fistula closure if treatment is preceded by EUA and seton placement...
  31. ncbi request reprint Systemic mastocytosis mimicking inflammatory bowel disease: A case report and discussion of gastrointestinal pathology in systemic mastocytosis
    Ahmed Bedeir
    Department of Pathology, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, USA
    Am J Surg Pathol 30:1478-82. 2006
    ....
  32. ncbi request reprint Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
    Miguel Regueiro
    University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 98:1821-6. 2003
    ..The aim of this study was to assess the response of medically refractory pyoderma gangrenosum to infliximab...
  33. doi request reprint Mucosal IgG4 Cell Infiltration in Ulcerative Colitis Is Linked to Disease Activity and Primary Sclerosing Cholangitis
    Amit Raina
    Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania
    Inflamm Bowel Dis 19:1232-7. 2013
    ..We systematically evaluated IgG4 cell distribution in colonic mucosal biopsies of patients with IBD and correlated histological findings with disease pattern and mucosal inflammation...
  34. doi request reprint Management of persistent gastric bleeding in a patient with Glanzmann's thrombasthenia
    Suzanne Bakdash
    Division of Transfusion Medicine, Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Am J Hematol 83:411-5. 2008